Christine Marie Veenstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christine Marie Veenstra has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Sarah T. Hawley
University of Michigan, Ann Arbor, MI
8 shared publications Sarah T. Hawley
Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor
7 shared publications- Ann S. Hamilton
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA
6 shared publications - Kevin C. Ward
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
6 shared publications - Paul Abrahamse
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI
6 shared publications - Steven J. Katz
Department of Internal Medicine, University of Michigan, Ann Arbor, MI
5 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers
Background: Molecular underpinnings and clinical characteristics of ERBB2/HER2-mutated colorectal cancers (CRCs) remain poorly understood. We aimed to comprehensively characterize the genomic landscape and clinical features of ERBB2/HER2-mutated CRC and to compare them with those of ERBB2/HER2-amplified CRC. Patients and methods: We analyzed cBioPortal data from 4348 CRC patients with available ERBB2/HER2 profiling. Clinicodemographic features, microsatellite instability (MSI), tumor mutational burden, and alterations in 94 cancer-associated genes were evaluated using chi-square/Fisher’s exact test, Kruskal–Wallis test, and hierarchical clustering. Results: ERBB2/HER2 putative driver mutations were identified in 95 patients (2.2%), amplifications in 87 (2.0%), and wild-type status in 4166 (95.8%). In the overall cohort, ERBB2/HER2-mutated tumors demonstrated significant KRAS enrichment (50.5%) compared to wild-type (37.7%; P = .014) and amplified tumors (18.4%; P < .001), alongside MSI enrichment (37.2% vs 1.6%; P < .001), elevated tumor mutational burden, and right-sided predominance. ERBB2/HER2-mutated tumors also showed broad driver co-alterations largely reflecting their MSI background. In contrast, ERBB2/HER2-amplified tumors exhibited left-sided predominance, with microsatellite stable (MSS)-restricted analyses revealing selective mutual exclusivity with KRAS (Log2 OR = −1.58; q = 0.019) and TP53 co-occurrence (Log2 OR = 2.04; q = 0.019). Hierarchical clustering confirmed that mutated and amplified tumors consistently occupy separate clusters across anatomical sites. Conclusion: ERBB2/HER2 mutations and amplifications represent molecularly and clinically distinct subgroups. ERBB2/HER2-mutated tumors are characterized by an MSI-enriched, hypermutated background with frequent concurrent KRAS alterations, whereas amplified tumors exhibit selective KRAS mutual exclusivity and TP53 co-occurrence. These exploratory findings support alteration-specific therapeutic strategies in CRC.
- 31 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Open AccessGenomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers
Background: Molecular underpinnings and clinical characteristics of ERBB2/HER2-mutated colorectal cancers (CRCs) remain poorly understood. We aimed to comprehensively characterize the genomic landscape and clinical features of ERBB2/HER2-mutated CRC and to compare them with those of ERBB2/HER2-amplified CRC. Patients and methods: We analyzed cBioPortal data from 4348 CRC patients with available ERBB2/HER2 profiling. Clinicodemographic features, microsatellite instability (MSI), tumor mutational burden, and alterations in 94 cancer-associated genes were evaluated using chi-square/Fisher’s exact test, Kruskal–Wallis test, and hierarchical clustering. Results: ERBB2/HER2 putative driver mutations were identified in 95 patients (2.2%), amplifications in 87 (2.0%), and wild-type status in 4166 (95.8%). In the overall cohort, ERBB2/HER2-mutated tumors demonstrated significant KRAS enrichment (50.5%) compared to wild-type (37.7%; P = .014) and amplified tumors (18.4%; P < .001), alongside MSI enrichment (37.2% vs 1.6%; P < .001), elevated tumor mutational burden, and right-sided predominance. ERBB2/HER2-mutated tumors also showed broad driver co-alterations largely reflecting their MSI background. In contrast, ERBB2/HER2-amplified tumors exhibited left-sided predominance, with microsatellite stable (MSS)-restricted analyses revealing selective mutual exclusivity with KRAS (Log2 OR = −1.58; q = 0.019) and TP53 co-occurrence (Log2 OR = 2.04; q = 0.019). Hierarchical clustering confirmed that mutated and amplified tumors consistently occupy separate clusters across anatomical sites. Conclusion: ERBB2/HER2 mutations and amplifications represent molecularly and clinically distinct subgroups. ERBB2/HER2-mutated tumors are characterized by an MSI-enriched, hypermutated background with frequent concurrent KRAS alterations, whereas amplified tumors exhibit selective KRAS mutual exclusivity and TP53 co-occurrence. These exploratory findings support alteration-specific therapeutic strategies in CRC.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2600041
Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants
PURPOSE: Germline testing is underutilized and varies by cancer diagnosis. We hypothesized that patient and clinician involvement in cascade testing of relatives varies by the cancer susceptibility (breast v gastrointestinal [GI]) of the affected gene. METHODS: All patients diagnosed with cancer in Georgia or California during 2018-2019 and reported to SEER registries, who were linked to a pathogenic variant (PV) result from testing laboratories, were surveyed 4.5 years postdiagnosis about (1) clinician involvement in result communication to relatives, (2) attitudes about result communication, (3) result communication to relatives, and (4) relatives' testing. PVs were categorized by primary association with breast ( BRCA1, BRCA2, ATM, BARD1, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 ) or GI cancers ( MLH1, MSH2, MSH6, PMS2, EPCAM, APC, BMPR1A, CDKN2A, GREM1, POLD1, POLE, SMAD4 ). RESULTS: A total of 4,080 patients were surveyed; 2,183 responded (53.5%). Most had PVs associated with breast (83.4%) versus GI cancers (16.6%). Most (85.0%) reported a genetic counseling visit. Genetic counselors were most involved in encouraging family communication (71.5%, v oncologists 33.4%, surgeons 19.4%), advising how to talk with relatives (55.0%, versus oncologists 18.0%, surgeons 9.1%), and talking directly with relatives (33.4%, v oncologists 12.6%, surgeons 7.0%). Most patients considered sharing results their responsibility (86.8%); they notified 86.8% of first-degree and 44.9% of second-degree relatives. Nearly one third (29.0%) of patients reported that no relative was tested, whereas 18.3% reported that four or more relatives were tested. Outcomes did not differ by affected gene or cancer type ( P > .1). CONCLUSION: Patients with cancer are motivated to communicate PV results to relatives. However, few clinicians are involved and relatives' testing remains low. Novel care delivery models are needed to advance cascade testing and precision risk reduction.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2600041
Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants
PURPOSE: Germline testing is underutilized and varies by cancer diagnosis. We hypothesized that patient and clinician involvement in cascade testing of relatives varies by the cancer susceptibility (breast v gastrointestinal [GI]) of the affected gene. METHODS: All patients diagnosed with cancer in Georgia or California during 2018-2019 and reported to SEER registries, who were linked to a pathogenic variant (PV) result from testing laboratories, were surveyed 4.5 years postdiagnosis about (1) clinician involvement in result communication to relatives, (2) attitudes about result communication, (3) result communication to relatives, and (4) relatives' testing. PVs were categorized by primary association with breast ( BRCA1, BRCA2, ATM, BARD1, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 ) or GI cancers ( MLH1, MSH2, MSH6, PMS2, EPCAM, APC, BMPR1A, CDKN2A, GREM1, POLD1, POLE, SMAD4 ). RESULTS: A total of 4,080 patients were surveyed; 2,183 responded (53.5%). Most had PVs associated with breast (83.4%) versus GI cancers (16.6%). Most (85.0%) reported a genetic counseling visit. Genetic counselors were most involved in encouraging family communication (71.5%, v oncologists 33.4%, surgeons 19.4%), advising how to talk with relatives (55.0%, versus oncologists 18.0%, surgeons 9.1%), and talking directly with relatives (33.4%, v oncologists 12.6%, surgeons 7.0%). Most patients considered sharing results their responsibility (86.8%); they notified 86.8% of first-degree and 44.9% of second-degree relatives. Nearly one third (29.0%) of patients reported that no relative was tested, whereas 18.3% reported that four or more relatives were tested. Outcomes did not differ by affected gene or cancer type ( P > .1). CONCLUSION: Patients with cancer are motivated to communicate PV results to relatives. However, few clinicians are involved and relatives' testing remains low. Novel care delivery models are needed to advance cascade testing and precision risk reduction.
- 23 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501082
Implementation and Evaluation of Close to Me, a Novel Outpatient Clinic and Home-Based Infusion Therapy Program Through the Veterans Health Administration
PURPOSE: Travel-related burdens are an ongoing issue for cancer and other specialty care patients. To address these issues, the Veterans Health Administration (VA) National Oncology Program sponsors the Close to Me (CTM) care model to facilitate novel care delivery strategies throughout the VA system. The VA Ann Arbor Healthcare System (VAAAHS) Hematology-Oncology Clinic implemented CTM, using local VA clinics and home-based therapies to reduce travel burdens for Veterans. METHODS: Veterans eligible for CTM included those receiving infusion treatments through the VAAAHS who lived near a VA community-based outpatient clinic (CBOC) regardless of primary specialty, and Veterans with multiple myeloma receiving bortezomib subcutaneously. After enrollment, Veterans received their infusion therapies at a CBOC, administered by traveling VAAAHS infusion nurses. Veterans with multiple myeloma self-administered bortezomib at home under direct observation of an infusion nurse. RESULTS: From October 2024 to June 2025, we enrolled 102 patients in the CTM program. Patients saved 21,840 total travel miles, for an estimated $8,954 of travel-related costs saved by patients receiving care at a local clinic or at home. A total of 261 treatment visits were completed, with an estimated $403,432 of potential drug cost-savings on the basis of VA versus Medicare Average Sales Pricing File data. There were no serious adverse events related to patients receiving therapy locally or at home, with overall 98.5% treatment adherence. Patient satisfaction was high, with most patients rating their experience as excellent and reporting that they would recommend this service to others. CONCLUSION: The VAAAHS CTM program demonstrates the safety and feasibility of a local clinic and home-based infusion program through the VA, resulting in significant travel and cost-savings for patients. Our experience addresses issues related to the delivery of cancer care in both VA and non-VA settings.
- 23 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501082
Implementation and Evaluation of Close to Me, a Novel Outpatient Clinic and Home-Based Infusion Therapy Program Through the Veterans Health Administration
PURPOSE: Travel-related burdens are an ongoing issue for cancer and other specialty care patients. To address these issues, the Veterans Health Administration (VA) National Oncology Program sponsors the Close to Me (CTM) care model to facilitate novel care delivery strategies throughout the VA system. The VA Ann Arbor Healthcare System (VAAAHS) Hematology-Oncology Clinic implemented CTM, using local VA clinics and home-based therapies to reduce travel burdens for Veterans. METHODS: Veterans eligible for CTM included those receiving infusion treatments through the VAAAHS who lived near a VA community-based outpatient clinic (CBOC) regardless of primary specialty, and Veterans with multiple myeloma receiving bortezomib subcutaneously. After enrollment, Veterans received their infusion therapies at a CBOC, administered by traveling VAAAHS infusion nurses. Veterans with multiple myeloma self-administered bortezomib at home under direct observation of an infusion nurse. RESULTS: From October 2024 to June 2025, we enrolled 102 patients in the CTM program. Patients saved 21,840 total travel miles, for an estimated $8,954 of travel-related costs saved by patients receiving care at a local clinic or at home. A total of 261 treatment visits were completed, with an estimated $403,432 of potential drug cost-savings on the basis of VA versus Medicare Average Sales Pricing File data. There were no serious adverse events related to patients receiving therapy locally or at home, with overall 98.5% treatment adherence. Patient satisfaction was high, with most patients rating their experience as excellent and reporting that they would recommend this service to others. CONCLUSION: The VAAAHS CTM program demonstrates the safety and feasibility of a local clinic and home-based infusion program through the VA, resulting in significant travel and cost-savings for patients. Our experience addresses issues related to the delivery of cancer care in both VA and non-VA settings.
- Open Access
- 16 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (7) , 1-13
Communication and fear of cancer recurrence in colorectal cancer survivors and their partners
Purpose: Little is known about how colorectal (CRC) survivors and their partners communicate about cancer or experience fear of cancer recurrence (FCR). To effectively support and guide survivors and partners, we designed a dyadic survey and investigated whether survivors’ health-related quality of life (HRQoL) was associated with dyadic discordance in communication or FCR. Methods: From 2019–2020 we surveyed survivors of stage III CRC and their partners. We measured dyadic cancer communication using the Lewis Mutuality and Interpersonal Sensitivity Scale. We asked dyads 3 questions about FCR. We measured survivors’ HrQoL using the PROMIS-29 + 2 profile, v 2.1. We used bivariate analyses and multivariable logistic regressions to compare survivor and partner responses, describe characteristics of discordant dyads, and assess associations between survivors’ HrQoL and discordance in cancer communication and FCR. Results: We analyzed data from 307 paired survivor-partner dyads (51% survivor response rate; 73% partner response rate). 29% dyads were discordant in cancer communication. 26% dyads were discordant in FCR. Greater discordance in cancer communication was associated with female survivor sex and greater partner educational attainment. Greater discordance in FCR was associated with younger survivor age and receipt of radiation (all p < 0.05). Worse survivor HRQoL was associated with greater discordance in FCR and receipt of radiation (all p < 0.01). Conclusions: Our findings highlight the complex dynamics dyads experience during CRC survivorship. While open communication is crucial, differing levels of shared fears and concerns can significantly impact health-related quality of life (HRQoL). Addressing these issues, especially FCR, can enhance patient-centered survivorship care.
- 16 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (7) , 1-13
Open AccessCommunication and fear of cancer recurrence in colorectal cancer survivors and their partners
Purpose: Little is known about how colorectal (CRC) survivors and their partners communicate about cancer or experience fear of cancer recurrence (FCR). To effectively support and guide survivors and partners, we designed a dyadic survey and investigated whether survivors’ health-related quality of life (HRQoL) was associated with dyadic discordance in communication or FCR. Methods: From 2019–2020 we surveyed survivors of stage III CRC and their partners. We measured dyadic cancer communication using the Lewis Mutuality and Interpersonal Sensitivity Scale. We asked dyads 3 questions about FCR. We measured survivors’ HrQoL using the PROMIS-29 + 2 profile, v 2.1. We used bivariate analyses and multivariable logistic regressions to compare survivor and partner responses, describe characteristics of discordant dyads, and assess associations between survivors’ HrQoL and discordance in cancer communication and FCR. Results: We analyzed data from 307 paired survivor-partner dyads (51% survivor response rate; 73% partner response rate). 29% dyads were discordant in cancer communication. 26% dyads were discordant in FCR. Greater discordance in cancer communication was associated with female survivor sex and greater partner educational attainment. Greater discordance in FCR was associated with younger survivor age and receipt of radiation (all p < 0.05). Worse survivor HRQoL was associated with greater discordance in FCR and receipt of radiation (all p < 0.01). Conclusions: Our findings highlight the complex dynamics dyads experience during CRC survivorship. While open communication is crucial, differing levels of shared fears and concerns can significantly impact health-related quality of life (HRQoL). Addressing these issues, especially FCR, can enhance patient-centered survivorship care.
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (6) , 791-800
Oncology and Primary Care Involvement in Breast Cancer Survivorship Care More Than 5 Years After Initial Treatment
PURPOSE: Very little is known about primary care involvement in the care of cancer survivors beyond the initial 5 years post-treatment when transitioning to primary care is guideline-recommended for many survivors. METHODS: The ICanCare study is a longitudinal survey of women diagnosed with breast cancer in 2014-2015 identified in the Georgia and Los Angeles SEER registries. Women were surveyed during initial treatment and again approximately 6 years later in survivorship (2021-2022; n = 1,412, 60% response rate). Respondents were asked which provider led their survivorship care (oncology, shared care, primary care provider [PCP]) and PCP management of eight common survivorship issues (range, 0-32). Multivariable-adjusted associations of participant characteristics with survivorship care delivery and PCP management of survivorship issues were evaluated using logistic and linear regression models, respectively. RESULTS: Over half of the women (57.2%) reported oncologist-led survivorship care delivery, 20.5% shared care, and 22.4% PCP-led. PCP management of survivorship issues was moderate (mean, 11.4, 95% CI, 11.0 to 11.8) and was highest (often/always discussed) for medication management (50.1%), improving physical activity (49.1%), and chronic disease management (43.6%). Greater confidence in PCP's ability to manage survivorship care ( v no or little confidence) was associated with PCP-led delivery ( P = .01) and more PCP management of survivorship issues ( P < .0001). CONCLUSION: In this diverse cohort of breast cancer survivors, primary care involvement in survivorship care delivery and management of common survivorship issues remains low even more than 5 years after completing treatment and little variation was seen across survivor sociodemographic or clinical characteristics. Confidence in PCP ability to manage survivorship care was found to be important and may represent an opportunity to foster transition to primary care-led survivorship care delivery.
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (6) , 791-800
Oncology and Primary Care Involvement in Breast Cancer Survivorship Care More Than 5 Years After Initial Treatment
PURPOSE: Very little is known about primary care involvement in the care of cancer survivors beyond the initial 5 years post-treatment when transitioning to primary care is guideline-recommended for many survivors. METHODS: The ICanCare study is a longitudinal survey of women diagnosed with breast cancer in 2014-2015 identified in the Georgia and Los Angeles SEER registries. Women were surveyed during initial treatment and again approximately 6 years later in survivorship (2021-2022; n = 1,412, 60% response rate). Respondents were asked which provider led their survivorship care (oncology, shared care, primary care provider [PCP]) and PCP management of eight common survivorship issues (range, 0-32). Multivariable-adjusted associations of participant characteristics with survivorship care delivery and PCP management of survivorship issues were evaluated using logistic and linear regression models, respectively. RESULTS: Over half of the women (57.2%) reported oncologist-led survivorship care delivery, 20.5% shared care, and 22.4% PCP-led. PCP management of survivorship issues was moderate (mean, 11.4, 95% CI, 11.0 to 11.8) and was highest (often/always discussed) for medication management (50.1%), improving physical activity (49.1%), and chronic disease management (43.6%). Greater confidence in PCP's ability to manage survivorship care ( v no or little confidence) was associated with PCP-led delivery ( P = .01) and more PCP management of survivorship issues ( P < .0001). CONCLUSION: In this diverse cohort of breast cancer survivors, primary care involvement in survivorship care delivery and management of common survivorship issues remains low even more than 5 years after completing treatment and little variation was seen across survivor sociodemographic or clinical characteristics. Confidence in PCP ability to manage survivorship care was found to be important and may represent an opportunity to foster transition to primary care-led survivorship care delivery.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (13) , 1587-1596
Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM , CHEK2 , or PALB2
PURPOSE: Oncologists encounter patients with pathogenic variants (PVs) in ATM , CHEK2 , or PALB2 , but little is known about their cancer mortality. METHODS: Patients who were 20 years or older, diagnosed in 2013-2019 with breast, colorectal, or pancreatic cancer, and reported to SEER registries in California and Georgia were linked to germline genetic testing results from four clinical laboratories and followed through 2021. Multivariable models of cancer mortality were fit; for each cancer, the reference group was the average hazard across all genetically tested patients with that diagnosis. Each cancer was modeled separately, followed by a single model that interacted the cancer type with all covariates. In addition to fixed effects models, random effects models were used as a regularization approach to reduce overfitting. RESULTS: A total of 70,272 tested patients with breast (48,473 estrogen receptor–/progesterone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative; 9,957 HER2-positive; 11,842 triple-negative) cancer, 5,822 with colorectal cancer, and 1,861 with pancreatic cancer were analyzed; the mean follow-up was 3.9 years. Patients with ATM , CHEK2 , or PALB2 PVs had no differences in breast, colorectal, or pancreatic cancer mortality. Patients with ATM PVs in triple-negative breast cancer appeared to have higher mortality in fixed effects models (hazard ratio [HR], 3.7 [95% CI, 1.8 to 7.8]), but not in random effects models (HR, 1.2 [95% CI, 0.8 to 1.6]) that reduce overfitting. Patients with BRCA1 / 2 PVs had lower triple-negative breast cancer mortality in both models (fixed HR, 0.6 [95% CI, 0.5 to 0.9], random HR, 0.7 [95% CI, 0.6 to 0.8]). Patients with Lynch syndrome gene PVs had lower colorectal cancer mortality in both models (fixed HR, 0.5 [95% CI, 0.4 to 0.8], random HR, 0.7 [95% CI, 0.5 to 0.9]). CONCLUSION: Patients with ATM , CHEK2 , or PALB2 PVs had similar breast, colorectal, and pancreatic cancer mortality to the average genetically tested patient with their cancer type.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (13) , 1587-1596
Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM , CHEK2 , or PALB2
PURPOSE: Oncologists encounter patients with pathogenic variants (PVs) in ATM , CHEK2 , or PALB2 , but little is known about their cancer mortality. METHODS: Patients who were 20 years or older, diagnosed in 2013-2019 with breast, colorectal, or pancreatic cancer, and reported to SEER registries in California and Georgia were linked to germline genetic testing results from four clinical laboratories and followed through 2021. Multivariable models of cancer mortality were fit; for each cancer, the reference group was the average hazard across all genetically tested patients with that diagnosis. Each cancer was modeled separately, followed by a single model that interacted the cancer type with all covariates. In addition to fixed effects models, random effects models were used as a regularization approach to reduce overfitting. RESULTS: A total of 70,272 tested patients with breast (48,473 estrogen receptor–/progesterone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative; 9,957 HER2-positive; 11,842 triple-negative) cancer, 5,822 with colorectal cancer, and 1,861 with pancreatic cancer were analyzed; the mean follow-up was 3.9 years. Patients with ATM , CHEK2 , or PALB2 PVs had no differences in breast, colorectal, or pancreatic cancer mortality. Patients with ATM PVs in triple-negative breast cancer appeared to have higher mortality in fixed effects models (hazard ratio [HR], 3.7 [95% CI, 1.8 to 7.8]), but not in random effects models (HR, 1.2 [95% CI, 0.8 to 1.6]) that reduce overfitting. Patients with BRCA1 / 2 PVs had lower triple-negative breast cancer mortality in both models (fixed HR, 0.6 [95% CI, 0.5 to 0.9], random HR, 0.7 [95% CI, 0.6 to 0.8]). Patients with Lynch syndrome gene PVs had lower colorectal cancer mortality in both models (fixed HR, 0.5 [95% CI, 0.4 to 0.8], random HR, 0.7 [95% CI, 0.5 to 0.9]). CONCLUSION: Patients with ATM , CHEK2 , or PALB2 PVs had similar breast, colorectal, and pancreatic cancer mortality to the average genetically tested patient with their cancer type.
- 31 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1573-1582
Extended endocrine therapy use and decision making after breast cancer diagnosis
Background: Adjuvant endocrine therapy is recommended to extend beyond 5 years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision making about extended endocrine therapy. Methods: Women aged 20-79 years diagnosed with stage I-II breast cancer in 2014-2015 and reported to Georgia and Los Angeles County Surveillance, Epidemiology, and End Results registries were surveyed at 7 months and again at 6 years postdiagnosis (n = 2361; response rate = 60%). Women with estrogen receptor–positive and/or progesterone receptor–positive disease were asked about their decision whether to continue therapy. Results: Of 831 women, 591 had completed or were completing 5 years of endocrine therapy. Among those who had decided (n = 557), 46.9% decided to continue (39.4% stage I; 62.4% stage II). On multivariable analysis, factors associated with continuation for stage I were as follows: worry about recurrence (adjusted odds ratio [aOR] = 3.35, 95% confidence interval [CI] = 1.78 to 6.32), desire for most extensive treatment (aOR = 2.15, 95% CI = 1.1 to 4.14), and primary care physician participation (aOR = 4.30, 95% CI = 2.22 to 8.32). Side effects were inversely associated with continuation (stage I: aOR = 0.21, 95% CI = 0.11 to 0.41). Associations were similar for stage II; for stage I only, bilateral mastectomy and chemotherapy were associated with continuation. Decision to continue did not vary by race, ethnicity, or demographic factors. Conclusions: Nearly 40% of women with stage I breast cancer and two-thirds with stage II decided to extend endocrine therapy. Decision making was influenced by patient values and varied little by stage. These results can inform physician-patient discussion about extending endocrine therapy.
- 31 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1573-1582
Extended endocrine therapy use and decision making after breast cancer diagnosis
Background: Adjuvant endocrine therapy is recommended to extend beyond 5 years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision making about extended endocrine therapy. Methods: Women aged 20-79 years diagnosed with stage I-II breast cancer in 2014-2015 and reported to Georgia and Los Angeles County Surveillance, Epidemiology, and End Results registries were surveyed at 7 months and again at 6 years postdiagnosis (n = 2361; response rate = 60%). Women with estrogen receptor–positive and/or progesterone receptor–positive disease were asked about their decision whether to continue therapy. Results: Of 831 women, 591 had completed or were completing 5 years of endocrine therapy. Among those who had decided (n = 557), 46.9% decided to continue (39.4% stage I; 62.4% stage II). On multivariable analysis, factors associated with continuation for stage I were as follows: worry about recurrence (adjusted odds ratio [aOR] = 3.35, 95% confidence interval [CI] = 1.78 to 6.32), desire for most extensive treatment (aOR = 2.15, 95% CI = 1.1 to 4.14), and primary care physician participation (aOR = 4.30, 95% CI = 2.22 to 8.32). Side effects were inversely associated with continuation (stage I: aOR = 0.21, 95% CI = 0.11 to 0.41). Associations were similar for stage II; for stage I only, bilateral mastectomy and chemotherapy were associated with continuation. Decision to continue did not vary by race, ethnicity, or demographic factors. Conclusions: Nearly 40% of women with stage I breast cancer and two-thirds with stage II decided to extend endocrine therapy. Decision making was influenced by patient values and varied little by stage. These results can inform physician-patient discussion about extending endocrine therapy.
- 12 July 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (7) , 837-845
Survival Prognostication in Patients with Differentiated Thyroid Cancer and Distant Metastases: A SEER Population-Based Study
Background: For patients with thyroid cancer, distant metastasis is a significant predictor of poor outcome. Since distant metastasis occurs in less than 10% of patients with differentiated thyroid cancer, correlates of survival in this vulnerable patient population remain understudied. This study aimed to identify prognostic groups among patients with differentiated thyroid cancer and distant metastases and to determine the role of, and interactions between, patient and tumor characteristics in determining survival. Methods: We identified adult patients diagnosed with differentiated thyroid cancer with distant metastases from the U.S. SEER-17 cancer registry (2010–2019). Analyses were performed using Cox proportional hazards regression, survival trees, and random survival forest. Relative importance of patient and tumor factors important for disease-specific and overall survival was assessed based on the random survival forest analyses. Results: Cohort consisted of 2411 patients with differentiated thyroid cancer with distant metastases followed for a median of 62 months. Most common histopathologic subtype (86.0%) was papillary thyroid cancer, and the most common sites of distant metastasis were the lungs (33.7%) and bone (18.9%). Cox proportional hazards model illustrated significant associations between survival and the following: patient age ( p < 0.001), tumor size ( p < 0.01), and site of distant metastasis ( p < 0.05). Survival tree analyses identified three distinct prognostic groups based on disease-specific survival (DSS) (5-year survival of the prognostic groups was 92%, 64%, and 41%; p < 0.001) and four distinct prognostic groups based on overall survival (OS) (5-year survival of the prognostic groups was 96%, 84%, 57%, and 31%; p < 0.001). The first split in the survival trees for DSS and OS was by age at diagnosis (≤57 years vs. ≥58 years) with subsequent splits based on presence/absence of lung metastases, tumor size (≤4 cm vs. >4 cm), and patient age. A total of 558 patients (23.1%) died from thyroid cancer, and 757 patients (31.4%) died from all causes during the study period. Conclusions: This study identifies distinct prognostic groups for patients with differentiated thyroid cancer with distant metastases and highlights the importance of patient age, lung metastases, and tumor size for determining both disease-specific and overall survival. These findings inform risk stratification and treatment decision-making in this understudied patient population.
- 12 July 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (7) , 837-845
Survival Prognostication in Patients with Differentiated Thyroid Cancer and Distant Metastases: A SEER Population-Based Study
Background: For patients with thyroid cancer, distant metastasis is a significant predictor of poor outcome. Since distant metastasis occurs in less than 10% of patients with differentiated thyroid cancer, correlates of survival in this vulnerable patient population remain understudied. This study aimed to identify prognostic groups among patients with differentiated thyroid cancer and distant metastases and to determine the role of, and interactions between, patient and tumor characteristics in determining survival. Methods: We identified adult patients diagnosed with differentiated thyroid cancer with distant metastases from the U.S. SEER-17 cancer registry (2010–2019). Analyses were performed using Cox proportional hazards regression, survival trees, and random survival forest. Relative importance of patient and tumor factors important for disease-specific and overall survival was assessed based on the random survival forest analyses. Results: Cohort consisted of 2411 patients with differentiated thyroid cancer with distant metastases followed for a median of 62 months. Most common histopathologic subtype (86.0%) was papillary thyroid cancer, and the most common sites of distant metastasis were the lungs (33.7%) and bone (18.9%). Cox proportional hazards model illustrated significant associations between survival and the following: patient age ( p < 0.001), tumor size ( p < 0.01), and site of distant metastasis ( p < 0.05). Survival tree analyses identified three distinct prognostic groups based on disease-specific survival (DSS) (5-year survival of the prognostic groups was 92%, 64%, and 41%; p < 0.001) and four distinct prognostic groups based on overall survival (OS) (5-year survival of the prognostic groups was 96%, 84%, 57%, and 31%; p < 0.001). The first split in the survival trees for DSS and OS was by age at diagnosis (≤57 years vs. ≥58 years) with subsequent splits based on presence/absence of lung metastases, tumor size (≤4 cm vs. >4 cm), and patient age. A total of 558 patients (23.1%) died from thyroid cancer, and 757 patients (31.4%) died from all causes during the study period. Conclusions: This study identifies distinct prognostic groups for patients with differentiated thyroid cancer with distant metastases and highlights the importance of patient age, lung metastases, and tumor size for determining both disease-specific and overall survival. These findings inform risk stratification and treatment decision-making in this understudied patient population.
- Open Access
- 7 May 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (11) , 12802-12812
Investigating potential disparities in clinical trial eligibility and enrollment at anNCI‐designated comprehensive cancer center
Background: Although barriers to trial accrual are well‐reported, few studies have explored trial eligibility and trial offers as potential drivers of disparities in cancer clinical trial enrollment.Methods: We identified patients with gastrointestinal (GI) or head/neck (HN) malignancies who were seen as new patients at the University of Michigan Health Rogel Cancer Center in 2016. By exhaustive review of the electronic medical record, we assessed the primary outcomes: (1) eligibility for, (2) documented offer of, and (3) enrollment in a clinical trial. All 41 of the clinical trials available to these patients were considered. Independent variables included clinical and non‐clinical patient‐related factors. We assessed associations between these variables and the primary outcomes using multivariable regression.Results: Of 1446 patients, 43% were female, 15% were over age 75, 6% were Black. 305 (21%) patients were eligible for a clinical trial. Among eligible patients, 154 (50%) had documentation of a trial offer and 90 (30%) enrolled. Among the GI cohort, bivariate analyses demonstrated that older age was associated with decreased trial eligibility. Bivariate analyses also demonstrated that Black race was associated with increased trial offer. After adjustment, patients 75 or older were less likely to be eligible for a clinical trial in the GI cohort; however, we found no significant associations between race and any of the outcomes after adjustment. Among eligible GI patients, we found no significant associations between non‐clinical factors and enrollment. Among the HN cohort, bivariate analyses demonstrated that female sex, older age, Black race, and unpartnered marital status were associated with decreased likelihood of trial offer; however, we found no significant associations between race, age, and marital status and any of the outcomes after adjustment. We found no significant associations between non‐clinical factors and eligibility after adjustment; however, women were less likely to be offered and to enroll in a clinical trial in the HN cohort.Conclusion: Factors associated with eligibility, documented offer, and enrollment differed between disease site cohorts at our institution. Future work is needed to ensure the equitable inclusion of women and elderly patients in clinical trials.
- 7 May 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (11) , 12802-12812
Open AccessInvestigating potential disparities in clinical trial eligibility and enrollment at anNCI‐designated comprehensive cancer center
Background: Although barriers to trial accrual are well‐reported, few studies have explored trial eligibility and trial offers as potential drivers of disparities in cancer clinical trial enrollment.Methods: We identified patients with gastrointestinal (GI) or head/neck (HN) malignancies who were seen as new patients at the University of Michigan Health Rogel Cancer Center in 2016. By exhaustive review of the electronic medical record, we assessed the primary outcomes: (1) eligibility for, (2) documented offer of, and (3) enrollment in a clinical trial. All 41 of the clinical trials available to these patients were considered. Independent variables included clinical and non‐clinical patient‐related factors. We assessed associations between these variables and the primary outcomes using multivariable regression.Results: Of 1446 patients, 43% were female, 15% were over age 75, 6% were Black. 305 (21%) patients were eligible for a clinical trial. Among eligible patients, 154 (50%) had documentation of a trial offer and 90 (30%) enrolled. Among the GI cohort, bivariate analyses demonstrated that older age was associated with decreased trial eligibility. Bivariate analyses also demonstrated that Black race was associated with increased trial offer. After adjustment, patients 75 or older were less likely to be eligible for a clinical trial in the GI cohort; however, we found no significant associations between race and any of the outcomes after adjustment. Among eligible GI patients, we found no significant associations between non‐clinical factors and enrollment. Among the HN cohort, bivariate analyses demonstrated that female sex, older age, Black race, and unpartnered marital status were associated with decreased likelihood of trial offer; however, we found no significant associations between race, age, and marital status and any of the outcomes after adjustment. We found no significant associations between non‐clinical factors and eligibility after adjustment; however, women were less likely to be offered and to enroll in a clinical trial in the HN cohort.Conclusion: Factors associated with eligibility, documented offer, and enrollment differed between disease site cohorts at our institution. Future work is needed to ensure the equitable inclusion of women and elderly patients in clinical trials.
- Top Cited Papers
- 3 April 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (4) , e235897
Financial Toxicity and Its Association With Health-Related Quality of Life Among Partners of Colorectal Cancer Survivors
Importance: Partners of colorectal cancer (CRC) survivors play a critical role in diagnosis, treatment, and survivorship. While financial toxicity (FT) is well documented among patients with CRC, little is known about long-term FT and its association with health-related quality of life (HRQoL) among their partners.Objective: To understand long-term FT and its association with HRQoL among partners of CRC survivors.Design, Setting, and Participants: This survey study incorporating a mixed-methods design consisted of a mailed dyadic survey with closed- and open-ended responses. In 2019 and 2020, we surveyed survivors who were 1 to 5 years from a stage III CRC diagnosis and included a separate survey for their partners. Patients were recruited from a rural community oncology practice in Montana, an academic cancer center in Michigan, and the Georgia Cancer Registry. Data analysis was performed from February 2022 to January 2023.Exposures: Three components of FT, including financial burden, debt, and financial worry.Main Outcomes and Measures: Financial burden was assessed with the Personal Financial Burden scale, whereas debt and financial worry were each assessed with a single survey item. We measured HRQoL using the PROMIS-29+2 Profile, version 2.1. We used multivariable regression analysis to assess associations of FT with individual domains of HRQoL. We used thematic analysis to explore partner perspectives on FT, and we merged quantitative and qualitative findings to explain the association between FT and HRQoL.Results: Of the 986 patients eligible for this study, 501 (50.8%) returned surveys. A total of 428 patients (85.4%) reported having a partner, and 311 partners (72.6%) returned surveys. Four partner surveys were returned without a corresponding patient survey, resulting in a total of 307 patient-partner dyads for this analysis. Among the 307 partners, 166 (56.1%) were aged younger than 65 years (mean [SD] age, 63.7 [11.1] years), 189 (62.6%) were women, and 263 (85.7%) were White. Most partners (209 [68.1%]) reported adverse financial outcomes. High financial burden was associated with worse HRQoL in the pain interference domain (mean [SE] score, −0.08 [0.04]; P = .03). Debt was associated with worse HRQoL in the sleep disturbance domain (−0.32 [0.15]; P = .03). High financial worry was associated with worse HRQoL in the social functioning (mean [SE] score, −0.37 [0.13]; P = .005), fatigue (−0.33 [0.15]; P = .03), and pain interference (−0.33 [0.14]; P = .02) domains. Qualitative findings revealed that in addition to systems-level factors, individual-level behavioral factors were associated with partner financial outcomes and HRQoL.Conclusions and Relevance: This survey study found that partners of CRC survivors experienced long-term FT that was associated with worse HRQoL. Multilevel interventions for both patients and partners are needed to address factors at individual and systemic levels and incorporate behavioral approaches.
- 3 April 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (4) , e235897
Top Cited PapersFinancial Toxicity and Its Association With Health-Related Quality of Life Among Partners of Colorectal Cancer Survivors
Importance: Partners of colorectal cancer (CRC) survivors play a critical role in diagnosis, treatment, and survivorship. While financial toxicity (FT) is well documented among patients with CRC, little is known about long-term FT and its association with health-related quality of life (HRQoL) among their partners.Objective: To understand long-term FT and its association with HRQoL among partners of CRC survivors.Design, Setting, and Participants: This survey study incorporating a mixed-methods design consisted of a mailed dyadic survey with closed- and open-ended responses. In 2019 and 2020, we surveyed survivors who were 1 to 5 years from a stage III CRC diagnosis and included a separate survey for their partners. Patients were recruited from a rural community oncology practice in Montana, an academic cancer center in Michigan, and the Georgia Cancer Registry. Data analysis was performed from February 2022 to January 2023.Exposures: Three components of FT, including financial burden, debt, and financial worry.Main Outcomes and Measures: Financial burden was assessed with the Personal Financial Burden scale, whereas debt and financial worry were each assessed with a single survey item. We measured HRQoL using the PROMIS-29+2 Profile, version 2.1. We used multivariable regression analysis to assess associations of FT with individual domains of HRQoL. We used thematic analysis to explore partner perspectives on FT, and we merged quantitative and qualitative findings to explain the association between FT and HRQoL.Results: Of the 986 patients eligible for this study, 501 (50.8%) returned surveys. A total of 428 patients (85.4%) reported having a partner, and 311 partners (72.6%) returned surveys. Four partner surveys were returned without a corresponding patient survey, resulting in a total of 307 patient-partner dyads for this analysis. Among the 307 partners, 166 (56.1%) were aged younger than 65 years (mean [SD] age, 63.7 [11.1] years), 189 (62.6%) were women, and 263 (85.7%) were White. Most partners (209 [68.1%]) reported adverse financial outcomes. High financial burden was associated with worse HRQoL in the pain interference domain (mean [SE] score, −0.08 [0.04]; P = .03). Debt was associated with worse HRQoL in the sleep disturbance domain (−0.32 [0.15]; P = .03). High financial worry was associated with worse HRQoL in the social functioning (mean [SE] score, −0.37 [0.13]; P = .005), fatigue (−0.33 [0.15]; P = .03), and pain interference (−0.33 [0.14]; P = .02) domains. Qualitative findings revealed that in addition to systems-level factors, individual-level behavioral factors were associated with partner financial outcomes and HRQoL.Conclusions and Relevance: This survey study found that partners of CRC survivors experienced long-term FT that was associated with worse HRQoL. Multilevel interventions for both patients and partners are needed to address factors at individual and systemic levels and incorporate behavioral approaches.